MIRALUMA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Miraluma, and what generic alternatives are available?
Miraluma is a drug marketed by Lantheus Medcl and is included in one NDA.
The generic ingredient in MIRALUMA is technetium tc-99m sestamibi kit. There are four drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the technetium tc-99m sestamibi kit profile page.
Summary for MIRALUMA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 4 |
| Clinical Trials: | 1 |
| Patent Applications: | 42 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | MIRALUMA at DailyMed |
Recent Clinical Trials for MIRALUMA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| M.D. Anderson Cancer Center | Early Phase 1 |
| National Cancer Institute (NCI) | Early Phase 1 |
| GE Healthcare | Early Phase 1 |
US Patents and Regulatory Information for MIRALUMA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lantheus Medcl | MIRALUMA | technetium tc-99m sestamibi kit | INJECTABLE;INJECTION | 019785-003 | May 23, 1997 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MIRALUMA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Lantheus Medcl | MIRALUMA | technetium tc-99m sestamibi kit | INJECTABLE;INJECTION | 019785-003 | May 23, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
| Lantheus Medcl | MIRALUMA | technetium tc-99m sestamibi kit | INJECTABLE;INJECTION | 019785-003 | May 23, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
| Lantheus Medcl | MIRALUMA | technetium tc-99m sestamibi kit | INJECTABLE;INJECTION | 019785-003 | May 23, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
| Lantheus Medcl | MIRALUMA | technetium tc-99m sestamibi kit | INJECTABLE;INJECTION | 019785-003 | May 23, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
| Lantheus Medcl | MIRALUMA | technetium tc-99m sestamibi kit | INJECTABLE;INJECTION | 019785-003 | May 23, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for MIRALUMA
See the table below for patents covering MIRALUMA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | S59500674 | ⤷ Try a Trial | |
| Japan | H07242615 | ETHER-SUBSTITUTED ISONITRILE AND ITS PREPARATION | ⤷ Try a Trial |
| South Africa | 8605828 | ⤷ Try a Trial | |
| Denmark | 174300 | ⤷ Try a Trial | |
| Mexico | 9203600 | ADUCTOS DE TRIS(ISONITRILO)COBRE(I) PARA PREPARAR COMPLEJOS DE RADIONUCLIDOS. | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for MIRALUMA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0107734 | SPC/GB93/166 | United Kingdom | ⤷ Try a Trial | SPC/GB93/166, EXPIRES: 20050816 |
| 1178838 | 300736 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: TILMANOCEPT, DESGEWENST GELABELD MET TECHNETIUM TC 99M; REGISTRATION NO/DATE: EU/1/14/955 20141119 |
| 0107734 | 93C0042 | Belgium | ⤷ Try a Trial | PROD. NAME TETRAKIS (2-METHOXY-ISOBUTYL-ISONITRILE). CUIVRE (I) TETRAFLUOROBORATE, DIHYDRATE DE CHLORURE STANNEUX, CHLORHYDRATE DE L-CYSTEINE (MONOHYDRATE); REG NO/DATE 923 IS 3 F 12/ 19900924 ; FIRST REG CC NO DATE IE PA 200/9/1 19900817 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
